<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34223884</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study.</ArticleTitle><Pagination><StartPage>1191</StartPage><EndPage>1198</EndPage><MedlinePgn>1191-1198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ciab611</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciab611</ELocationID><Abstract><AbstractText Label="BACKGROUND">Long COVID is defined as the persistence of symptoms beyond 3 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To better understand the long-term course and etiology of symptoms we analyzed a cohort of patients with COVID-19 prospectively.</AbstractText><AbstractText Label="METHODS">Patients were included at 5 months after acute COVID-19 in this prospective, noninterventional, follow-up study. Patients followed until 12 months after COVID-19 symptom onset (n&#x2005;=&#x2005;96; 32.3% hospitalized, 55.2% females) were included in this analysis of symptoms, quality of life (based on an SF-12 survey), laboratory parameters including antinuclear antibodies (ANAs), and SARS-CoV-2 antibody levels.</AbstractText><AbstractText Label="RESULTS">At month 12, only 22.9% of patients were completely free of symptoms and the most frequent symptoms were reduced exercise capacity (56.3%), fatigue (53.1%), dyspnea (37.5%), and problems with concentration (39.6%), finding words (32.3%), and sleeping (26.0%). Females showed significantly more neurocognitive symptoms than males. ANA titers were &#x2265;1:160 in 43.6% of patients at 12 months post-COVID-19 symptom onset, and neurocognitive symptom frequency was significantly higher in the group with an ANA titer &#x2265;1:160 versus &lt;1:160. Compared with patients without symptoms, patients with &#x2265;1 long-COVID symptom at 12 months did not differ significantly with respect to their SARS-CoV-2 antibody levels but had a significantly reduced physical and mental life quality compared with patients without symptoms.</AbstractText><AbstractText Label="CONCLUSIONS">Neurocognitive long-COVID symptoms can persist &#x2265;1 year after COVID-19 symptom onset and reduce life quality significantly. Several neurocognitive symptoms were associated with ANA titer elevations. This may indicate autoimmunity as a cofactor in etiology of long COVID.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>See&#xdf;le</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterboer</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ]), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hippchen</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ]), Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchner</LastName><ForeName>Marietta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Adeline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merle</LastName><ForeName>Uta</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1386-3350</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2022 Jun 10;74(11):2083-2084. doi: 10.1093/cid/ciab890</RefSource><PMID Version="1">34617982</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2022 Aug 24;75(1):e1208. doi: 10.1093/cid/ciac007</RefSource><PMID Version="1">34989807</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANA titers</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">life quality</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>5</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34223884</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pii">6315216</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NICE COVID-19 rapid guidelines. PharmacoEcon Outcomes News 2021;877:33. doi: 10.1007/s40274-021-7682-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40274-021-7682-3</ArticleId><ArticleId IdType="pmc">PMC8085796</ArticleId><ArticleId IdType="pubmed">33948079</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, et al. ; COVERSCAN Study Investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open 2021; 11:e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx V. Scientists set out to connect the dots on long COVID. Nat Methods 2021; 18:449&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081406</ArticleId><ArticleId IdType="pubmed">33911230</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med 2020; 383:1757&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13:873&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15362179</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998; 7:155&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9523497</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt J, Murugan R, Hippchen T, et al. . From multiplex serology to serolomics&#x2014;a novel approach to the antibody response ag ainst the SARS-CoV-2 proteome. Viruses 2021; 13: 749. doi: 10.3390/v13050749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050749</ArticleId><ArticleId IdType="pmc">PMC8147094</ArticleId><ArticleId IdType="pubmed">33923338</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012; 38:J109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">22079680</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Maldonado Slootjes S, Sellimi A, et al. . Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol 2021; 268:751&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Stobbione P, et al. . SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14:898&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun 2021; 4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Feltkamp TE, Smolen JS, et al. . Range of antinuclear antibodies in &#x201c;healthy&#x201d; individuals. Arthritis Rheum 1997; 40:1601&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324014</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, et al. . Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27:258&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al. . Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2020; 76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez JM, et al. ; COVID19-ALC Research Group. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect 2021; 82:378&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021; 93:1013&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, et al. . Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One 2020; 15:e0243882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732078</ArticleId><ArticleId IdType="pubmed">33306721</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020; 81:e4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Correa J, Rodriguez A. Divergent roles of antiself antibodies during infection. Trends Immunol 2018; 39:515&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386177</ArticleId><ArticleId IdType="pubmed">29724608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra PK, Bruiners N, Ukey R, et al. . Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells. medRxiv [Preprint]. April 14, 2021. 2021. doi:10.1101/2021.04.11.21255153. Accessed 4 May 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.11.21255153</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, et al. . Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med 2021. doi:10.7326/M21-1976.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1976</ArticleId><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>